Actavis Says Endo Cites Wrong Precedent In False Ad Suit

By Dani Kass (February 23, 2016, 6:16 PM EST) -- Endo Pharmaceuticals Inc. can't rely on the U.S. Supreme Court's 2014 Pom Wonderful decision to claim that its suit against Actavis Inc. over generic versions of the painkiller Opana ER is allowed under the federal false advertising statute, Actavis told a New Jersey federal court Monday....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!